Medical treatment of osteoporosis - Increasing options

Annals of the Academy of Medicine Singapore

Volumn 31, Issue 1, 2002, Pages 43-47

  Leong, Keng Hong ^a  

^a GLENEAGLES HOSPITAL   (Singapore)

Author keywords

Bisphosphonates; Calcitonin; Fracture risk; Hormone replacement therapy; Parathyroid hormone; Selective oestrogen receptor modulators

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; FLUORIDE; NANDROLONE; PARATHYROID HORMONE; PREDNISOLONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STANOZOLOL; STRONTIUM; VITAMIN D DERIVATIVE;

BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; REVIEW; SIDE EFFECT; SPINE FRACTURE; TREATMENT OUTCOME;

EID: 0036099560     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Consensus development conference: Prophylaxis and treatment of osteoporosis
2. The diagnosis of osteoporosis
3. Risk factors for proximal humerus, forearm and wrist fractures in elderly men and women: The Dubbo Osteoporosis Epidemiology Study
4. The epidemiology of osteoporosis. The oriental perspective in a world context
5. Risk factors for hip fractures in white women. Study of Osteoporotic Fractures Research Group
6. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
7. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
8. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
9. Dietary calcium intake, physical activity and the risk of vertebral fracture in Chinese
10. Calcium for prevention of osteoporotic fractures in postmenopausal women
11. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
12. Vitamin D3 and calcium to prevent hip fractures in the elderly women
13. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial
14. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
15. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
16. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
17. Effect of risedronate on the risk of hip fracture in elderly women
18. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
19. Effects of clodronate on vertebral fracture risk in osteoporosis: A 1-year interim analysis
20. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
21. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
22. Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis
23. Fluoride for the treatment of postmenopausal osteoporotic fractures: A meta-analysis
24. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation
25. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial
26. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
27. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials
28. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
29. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies
30. Effect of calcitonin on vertebral and other fractures
31. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
32. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study
33. Treatment of postmenopausal osteoporosis with calcitriol or calcium
34. Effects of nandrolone decanoate on bone mass in established osteoporosis
35. Management of male osteoporosis: Report of the UK Consensus Group
36. Alendronate for the treatment of osteoporosis in men
37. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures
38. Salmon calcitonin and calcium in the treatment of male osteoporosis: The effect on bone mineral density
39. Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption
40. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density
41. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update
42. Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis
43. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
44. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial
45. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
46. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
47. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss
48. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids
49. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin
50. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis
51. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis
52. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate
53. Osteoporosis - The need for a paradigm shift
54. How well are the community-living women treated for osteoporosis after hip fracture?